Gustave Roussy Prize 2027: A €200,000 Oncology Award — Half Unrestricted, Half for a New Research Project — Open to Researchers of Any Nationality by Direct Application

Gustave Roussy Prize 2027: A €200,000 Oncology Award — Half Unrestricted, Half for a New Research Project — Open to Researchers of Any Nationality by Direct Application

Most large international science prizes are closed shops. You cannot apply; someone has to nominate you, usually the head of an institute or a learned society, and the nomination paperwork is often heavier than a grant application. The Gustave Roussy Prize works differently. For the 2027 edition, Gustave Roussy — Europe’s leading cancer centre, based in Villejuif just south of Paris — is inviting researchers themselves to submit an application through an online form. The prize is worth €200,000, and applications close on 26 August 2026 at 4:00 p.m. CEST.

The award structure is worth understanding before you decide whether to spend an afternoon on it. The €200,000 is split in half: €100,000 goes to the laureate for their free use, and €100,000 is earmarked to support an innovative research project in oncology. That makes it simultaneously a personal honour and a working research grant — a combination that is rare at this size, and one that shapes how you should present yourself if you apply.

The prize is awarded by Fondation Gustave Roussy, with Laboratoires Pierre Fabre as founding sponsor. It was launched in 2025 to mark two anniversaries at once: the 150th anniversary of the birth of Professor Gustave Roussy, and the centenary of the institute that carries his name. Roussy is credited with establishing, in 1921, the first medical consultation dedicated specifically to patients with tumours — a small administrative act that helped invent oncology as a discipline. The prize is explicitly framed as a tribute to that lineage.

Key Details

What the Prize Actually Rewards

Read the wording on the official page closely, because it is doing real work. The prize goes to “a prominent figure in oncology research whose scientific breakthroughs in the fields of cancer diagnosis, treatment, or prevention have significantly improved patient care or led to a better understanding of the disease.”

Two things stand out. First, the scope covers prevention and diagnosis, not just treatment. Epidemiologists, screening researchers, imaging scientists, pathologists, and diagnostics developers are inside the frame, not on its edge. Prizes in oncology skew heavily toward therapeutics; this one does not, at least on paper.

Second, the phrase “significantly improved patient care” is the load-bearing criterion. Gustave Roussy repeats a version of it everywhere the prize is described: the award “highlights innovation and scientific commitment that led to tangible, lasting benefits for patients.” The institute’s own stated mission — to cure more patients, more effectively and more sustainably — is invoked as the alignment test. The jury evaluates on “scientific excellence and clinical impact,” and clinical impact is named as a distinct criterion, not folded into excellence.

The practical implication is direct. A strong citation record is necessary but not sufficient. The application that wins is the one that can draw a clean line from a discovery to something that changed for patients: a guideline, a licensed test, an approved therapy, a screening protocol, a de-escalation of toxic treatment, a shift in how a tumour type is classified and therefore treated.

The two laureates so far confirm this reading. The 2025 winner, Professor Charles Swanton, is known for work on tumour evolution, intratumour heterogeneity, and — in the last few years — on how air pollution promotes lung cancer in people who never smoked. The 2026 winner, Professor Luis Diaz Jr., is associated with work on mismatch-repair-deficient tumours, immunotherapy response, and circulating tumour DNA. Both are researchers whose findings changed clinical practice, not only the literature. If you are trying to calibrate the level of the award, that is your benchmark.

Who Should Apply — and Who Should Not

Good fit:

• Established researchers with a body of work, not a single promising paper, whose findings have reached patients through practice, policy, guidelines, or an approved product.
• Scientists in any discipline — basic, translational, clinical, epidemiological, computational — as long as the endpoint is cancer patient care. The call states explicitly that there is no distinction by discipline.
• Researchers outside Europe. “All nationalities and affiliations” is stated plainly, and the prize’s framing is international. There is no requirement to be affiliated with Gustave Roussy or with a French institution.
• Researchers who have a specific, fundable oncology project they want the second €100,000 to support.

Poor fit:

• Early-career researchers and postdocs. This is a recognition prize for people whose work has already landed. If you are early in your independent career, look instead at programmes structured for that stage — Gustave Roussy itself runs a separate GRF-CRIS Clinical Scientist Emerging Leader Programme, which is a different call with different criteria.
• Researchers whose work is genuinely excellent but whose patient-facing impact is still speculative. That is not a judgement on the science; it is a statement about what this particular jury is instructed to weigh.
• Teams looking for project funding as such. Half the money is tied to a project, but the award is made to a person for past impact. It is not a research grant competition.

How to Apply

The mechanics are unusually light for an award of this size.

1. Go to the official prize page at gustaveroussy.fr/en/gustave-roussy-prize and use the “To apply” link, or use the application-form link published in the 18 June 2026 call announcement. The form is hosted on Microsoft Forms.
2. Submit before the cut-off. The deadline is 26 August 2026 at 4:00 p.m. CEST — a mid-afternoon Central European deadline, which matters if you are applying from the Americas or Asia-Pacific. Four in the afternoon in Paris is 10:00 a.m. in New York and 11:00 p.m. in Tokyo on the same day.
3. Wait for jury review. An independent jury of international experts, described as independent of Gustave Roussy, assesses applications on scientific excellence and clinical impact.
4. The result is announced at the ceremony, held on 4 February 2027 to coincide with World Cancer Day. Gustave Roussy’s prize page names the Lido theatre as the venue; note that the same page carries an inconsistent year in that sentence, while the June 2026 call announcement gives the award date as 4 February 2027. Treat 4 February 2027 as the ceremony date and confirm the venue with the foundation if you need it for travel planning.

On required documents: Gustave Roussy has not published a public list of required attachments for the 2027 edition on either the prize page or the call announcement. Expect the form itself to define the requirements. Prepare, at minimum, a current full CV with publication list, and a concise statement of the impact of your work — and open the form early enough to see what it actually asks for rather than discovering the requirements on 26 August.

Preparing a Competitive Application

Because the submission is a form rather than a long dossier, the compression is the hard part. A few things to get right:

Lead with the change, not the chronology. Do not walk the reader through your career in order. Open with the specific thing that is different for patients because of your work, then explain the science that produced it. Juries reading dozens of applications form an impression in the first paragraph.

Quantify impact where you honestly can. Numbers of patients affected, guideline citations, regulatory approvals, adoption in national screening programmes, changes in survival or toxicity — these are the evidence that distinguishes “clinical impact” from “clinically relevant.” Where a number does not exist, name the concrete mechanism of adoption instead.

Treat the €100,000 project half seriously. If the form gives you space to describe the research the second half of the award would fund, use it to show a live, specific line of work — not a wish list. The word the foundation uses is “innovative.” A project that is a natural but unfunded extension of the work being recognised reads better than either a safe continuation or an unrelated pivot.

Write for a cross-disciplinary jury. The panel is international and explicitly not organised by discipline. Someone assessing your immunology will not necessarily be an immunologist. Jargon that is load-bearing in your field is friction here.

Do not assume the jury knows you. International reputation is uneven across regions and subfields. Say what you did, plainly, even if it feels like stating the obvious to your own community.

Common Mistakes

• Missing the CEST cut-off. A 4:00 p.m. Paris deadline eliminates the usual “end of day, my time” buffer. Submit the day before.
• Assuming you need a nominator. Some coverage of large science prizes conditions people to look for a sponsoring institution. The Gustave Roussy call invites researchers to submit their own application; do not wait for a nomination that the process does not require.
• Assuming it is only for French or European scientists. The awarding institution is French; the prize is not restricted by nationality or affiliation, and the 2026 laureate is US-based.
• Presenting the science without the patient. The single most common way to be excellent and still lose here is to submit a case for scientific significance that never crosses into patient benefit.
• Ignoring the prevention and diagnosis routes. Researchers in screening, early detection, and diagnostics sometimes self-select out of oncology prizes. This call names those fields directly.
• Leaving the project half blank or generic. Half of the money has a purpose attached. Treating that as an afterthought wastes the strongest differentiator available to you.

Frequently Asked Questions

Can I nominate someone else instead of applying myself? The published call describes researchers submitting their own applications. It does not describe a third-party nomination route. If you want to put a colleague forward, the practical step is to encourage them to apply and to offer supporting material; contact Fondation Gustave Roussy directly if you need confirmation on this point.

Is there an age or career-stage limit? None is published. In practice the award has gone to established, internationally recognised researchers.

Do I need to be affiliated with an institution? The call says the prize is open regardless of institutional affiliation. Realistically, a body of work with demonstrated clinical impact will normally sit within an institutional context.

Does the €100,000 research half have to be spent at Gustave Roussy? The official description says the sum supports “an innovative research project in oncology.” It does not state a host institution requirement. Confirm with the foundation before making commitments based on that money.

Can I apply in French? The prize is administered from France and the pages are published in both French and English. The English-language call is official. If language of submission matters to you, check the form.

Is the €100,000 personal award taxable? That depends on your country of residence and tax status, and the foundation does not publish guidance on it. If you are shortlisted, take local advice.

What if I applied in a previous edition and did not win? No re-application restriction is published. The prize is annual and the call reopens each year.

Official Links and Contact

• Prize page (primary source): https://www.gustaveroussy.fr/en/gustave-roussy-prize
• 2027 call announcement, published 18 June 2026: https://www.gustaveroussy.fr/en/news-gustave-roussy-prize-2027-call-applications-now-open
• Awarding body: Fondation Gustave Roussy, with Laboratoires Pierre Fabre as founding sponsor
• Postal address: Gustave Roussy, 114 rue Édouard-Vaillant, 94805 Villejuif Cedex, France
• Switchboard: +33 (0)1 42 11 42 11

A dedicated email address for prize enquiries is not published on the prize page. If you have a question the published material does not answer, route it through the institute’s general contact channels well before the August deadline rather than in the final week.

Next Steps

If you are considering the 2027 edition, the sequence is short. Open the application form this week so you know exactly what it asks for. Draft a one-page impact statement that names the specific clinical change your work produced. Update your CV and publication list. Decide what the €100,000 project half would fund, in one paragraph, specifically. Then submit before 26 August 2026, 4:00 p.m. CEST — and if the timing does not work this year, the call is annual, so note the ceremony on 4 February 2027 and watch for the 2028 announcement, which on the pattern of the last two editions should appear in mid-year.